VERAXA Biotech (NASDAQ: VRXA) announced it has received Scientific Advice from Germany’s Paul-Ehrlich-Institute regarding the underlying biology and proposed non-clinical development plan for its lead proprietary BiTAC-TCE cancer therapy program. The company said the regulatory feedback provides greater clarity on its proposed development strategy and indicates that the agency understands the biological rationale behind its dual-targeting, conditionally active BiTAC-TCE platform, representing an early step in advancing the program toward clinical development.
VERAXA also highlighted preclinical data presented at the American Association for Cancer Research Annual Meeting 2026 showing its lead BiTAC-TCE candidate selectively targeted cancer cells expressing both intended targets while sparing cells expressing only one target. According to the company, the studies demonstrated a favorable safety profile with efficacy comparable to a traditional T-cell engager, supporting the potential for an improved therapeutic index.
Questions around this news
What does Scientific Advice from a medicines regulator mean?
Scientific Advice is feedback from a regulatory authority on development plans or scientific questions for a medicine. It can help a company understand how the authority views proposed studies and what issues may need attention. It is not marketing authorization and does not, by itself, establish that a therapy is safe or effective.
What did VERAXA report about its cancer therapy candidate’s preclinical results?
The company said its preclinical studies found that the lead candidate selectively targeted cancer cells displaying both intended targets, while sparing cells displaying only one. It also reported a favorable safety profile and efficacy comparable to a traditional T-cell engager. The release described these findings as supporting the potential for an improved therapeutic index.
How does a dual-targeting T-cell engager work?
A T-cell engager is designed to bring a patient’s T cells into contact with target cells, such as cancer cells. A bispecific version can bind two different targets. A dual-targeting design may require both targets to be present for stronger activity, while conditional activation means the therapy is intended to become active only under specified biological conditions.
To view the full press release, visit https://ibn.fm/jpXam
About VERAXA Biotech AG
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
In brief
VERAXA Biotech says Germany’s Paul-Ehrlich-Institute has provided Scientific Advice on the biology and proposed non-clinical plan for its lead BiTAC-TCE cancer therapy program. The company describes the feedback as clarifying its development approach and as an early milestone toward clinical development. VERAXA also reported preclinical findings presented at the American Association for Cancer Research Annual Meeting 2026. According to the company, its candidate preferentially acted on cancer cells bearing both intended targets, while sparing cells with only one. The studies, the company says, showed safety results it considers favorable and efficacy comparable to a traditional T-cell engager. VERAXA says these findings support the potential for a better therapeutic index. The release does not provide a clinical development timeline or disclose detailed study figures.
Key takeaways
- Germany’s Paul-Ehrlich-Institute gave Scientific Advice on the program’s biology and proposed non-clinical development plan.
- VERAXA says the feedback clarifies its development approach and represents an early step toward clinical development.
- The company reported preclinical findings at the American Association for Cancer Research Annual Meeting 2026.
- VERAXA says its lead candidate acted on cells with both intended targets while sparing those with only one.
SEC filings
Earlier from VERAXA Biotech AG
- VERAXA Biotech (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development
- VERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership
- VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy
- VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
- VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline
